Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer

doi:10.4251/wjgo.v17.i12.112548

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 12

This Article

(30)

(47)

(0)

(10)

(719)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Dec 15, 2025; 17(12): 112548
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112548

Table 4 Clinical trial data for third-line treatment in advanced microsatellite stable/proficient mismatch repair colorectal cancer

Ref.	Treatment	mPFS, months	mOS, months	DCR, %	≥ grade 2 AE, %
CONCUR[3]	Regorafenib	3.2	8.8	51.0	54.0
TERRA[4]	TAS-102	2.0	7.8	44.0	45.8
FRESCO[6]	Fruquintinib	3.7	9.3	62.0	46.0
RAMTAS/IKF643 (ESMO 2024 LBA25)	TAS-102 + ramucirumab	2.37	7.46	39.4	55.9
SUNLIGHT[17]	TAS-102 + bevacizumab	5.6	10.8	76.6	72.0
RIN[18]	Regorafentib + ipilimumab + nivolumab	4.0	20.0	62.1	65.5 (irAE)
CAPability-01[15]	Chidamide + bevacizumab + PD-1	3.7	12.0	56.3	60.0
REGONIVO[14]	Regorafenib + nivolumab	7.9	NR	-	40

mPFS: Median progression-free survival; mOS: Median overall survival; DCR: Disease control rate; AE: Adverse event; PD-1: Programmed death 1; NR: Not reported; irAE: Immune-related adverse event.

Full Size Table

Citation: Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548
URL: https://www.wjgnet.com/1948-5204/full/v17/i12/112548.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i12.112548

Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548 [PMID: 41480198 DOI: 10.4251/wjgo.v17.i12.112548]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.